drugset / Trial / NCT03953807

A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated

NCT03953807 ↗

Phase 4 Completed 82 enrolled Allergan
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy and safety of OZURDEX in patients with Diabetic Macular Edema when used in a real world setting in Spain and Portugal.

Timeline

Start
2019-09-05
Primary completion
2022-07-04
Completion
2022-07-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 700 ug Intravitreal